Industry Gets Breathing Space For Post-Brexit Regulation In Northern Ireland
One-Year Phase-In Period Addresses Pharma’s ‘Cliff Edge’ Concerns
Executive Summary
The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.
You may also be interested in...
UK Industry Chief Insists On Need For More Clarity On Medicines Regulation
The post-Brexit agreement between the UK and the EU leaves some grey areas in the field of medicines regulation. The UK government is coming under pressure to clarify the situation.
‘Public Health Crisis’ Warning For Northern Ireland Over Post-Brexit Guidance
With the likelihood of a UK-EU trade deal still in the balance, the UK life sciences industry has called for clarification from UK and EU regulators regarding the regulatory situation in Northern Ireland from next year.
‘Public Health Crisis’ Warning For Northern Ireland Over Post-Brexit Guidance
With the likelihood of a UK-EU trade deal still in the balance, the UK life sciences industry has called for clarification from UK and EU regulators regarding the regulatory situation in Northern Ireland from next year.